Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech develops and manufactures biosimilar medicines for global markets. Company news centers on its approved and marketed biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, along with disclosed candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease and cancer.
Recurring updates cover financial results, annual reporting, FDA interactions tied to the Reykjavik manufacturing facility, biosimilar study results such as AVT80, supply and commercialization partnerships, intellectual-property settlements, executive changes and manufacturing-platform developments. Alvotech also reports on global commercial reach through partners across the United States, Europe, Japan, China and other international markets.
Alvotech (NASDAQ: ALVO) announced a successful merger with OACB, securing approximately $185 million in gross proceeds. The company reported $40.1 million in revenue for the first half of 2022, a significant rise from $2.0 million during the same period in 2021. Alvotech launched AVT02 (adalimumab) in Canada and Europe, and reported positive results from its clinical pipeline, including biosimilars to Stelara and Xolair. The company plans to transition its Icelandic listing to the Nasdaq Main Market and will hold a business update call on September 1, 2022.
Summary not available.
Alvotech (NASDAQ: ALVO) has initiated a confirmatory patient study for AVT03, a biosimilar candidate to Prolia® and Xgeva®. The study aims to establish clinical similarity in efficacy and safety for treating osteoporosis in postmenopausal women. Prolia® and Xgeva® had combined sales of nearly $5.3 billion in 2021. The multicenter study will involve around 476 women, with results expected after 12 to 18 months. Alvotech, focused on biosimilars, seeks to enhance access to affordable biologic treatments globally.
Alvotech (NASDAQ: ALVO), a global biotech firm focusing on biosimilars, announced participation in two investor conferences in September 2022. The leadership team will engage in fireside chats at Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 pm ET and at Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 2:15 pm ET. A replay of these discussions will be available on their website for 90 days. Alvotech aims to lead in the biosimilar sector with a pipeline of eight candidates addressing various medical conditions.
Alvotech (NASDAQ: ALVO), a global biotech company, has announced participation in two investor conferences in September 2022. The leadership team will engage in fireside chats at:
- Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 pm ET
- Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 2:15 pm ET
Webcast replays will be accessible on the Investors Section of Alvotech’s website for 90 days.
Alvotech (NASDAQ: ALVO) announced it will release its financial results for Q2 and the first half of 2022 on August 31, 2022, after U.S. market close. Following the release, a business update conference call and webcast will take place on September 1, 2022, at 8:00 am ET. Alvotech specializes in biosimilar medicines, with a pipeline of eight candidates targeting various diseases. The company emphasizes growth through strategic global partnerships across multiple regions, including the U.S., Europe, and Asia.
Alvotech (NASDAQ: ALVO), the first Icelandic company dual-listed in the U.S. and Iceland, is set to move its shares to the Nasdaq Main Market in Iceland. This transition, approved by its Board of Directors, aims to enhance visibility and may lead to inclusion in international indexes like FTSE Global All Cap. Alvotech's current portfolio targets over US$85 billion market potential across several therapeutic areas, including autoimmune disorders and cancer. The move is subject to a rigorous application process and aligns with the company's ambition to strengthen its market presence.
Alvotech (NASDAQ: ALVO) is set to transition its share listing from the First North Growth Market to the Nasdaq Main Market in Iceland. This move aims to enhance visibility and potential inclusion in both Icelandic and international indexes, particularly the FTSE Global All Cap. The decision comes after Alvotech became the first Icelandic company dual-listed in the U.S. and Iceland in June 2022. The company specializes in biosimilar medicines, with a product portfolio targeting an estimated total addressable market exceeding US$85 billion.
Alvogen announced a significant district court ruling in favor of its proposed generic version of Xifaxan®, a treatment for irritable bowel syndrome with diarrhea (IBS-D). This ruling advances Alvogen's goal of providing a more affordable alternative for patients. Robert Wessman, Chairman of Alvogen, expressed satisfaction with the decision, noting its importance in delivering accessible treatment options. Alvogen specializes in developing, manufacturing, and selling both generic and branded pharmaceutical products, and is committed to expanding its market presence.
Alvotech (NASDAQ: ALVO) announced the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®, aimed at evaluating its safety and tolerability in healthy adult males. The combined sales of Prolia® and Xgeva® approached $5.3 billion in 2021. This milestone expands Alvotech’s clinical portfolio, which now includes four products under development. The company emphasizes its mission to enhance access to affordable biologic medicines, as stated by Chief Scientific Officer Joseph McClellan.